Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6324062 | 0.91 | CA2 (0.33) | CA2MAPTNPC1RAB9ACHRNA7 | |
| SCHEMBL6325868 | 0.89 | HSD17B10 (0.32) | CA2MAPTNPC1RAB9AHSD17B10 | |
| SCHEMBL6254565 | 0.85 | HSD17B10 (0.37) | CA2MAPTNPC1RAB9ACHRNA7 | |
| SCHEMBL6320298 | 0.85 | HSD17B10 (0.33) | CA2MAPTNPC1RAB9AHSD17B10 | |
| SCHEMBL6256841 | 0.83 | CA2 (0.33) | CA2MAPTNPC1RAB9AHSD17B10 | |
| SCHEMBL6256850 | 0.82 | CA2 (0.31) | CA2MAPTHSD17B10 | |
| SCHEMBL6318976 | 0.73 | CA2 (0.32) | CA2CHRNA7 | |
| SCHEMBL6318633 | 0.73 | MAPT (0.34) | CA2MAPTNPC1RAB9ACHRNA7 | |
| SCHEMBL6318085 | 0.72 | LMNA (0.31) | — | |
| SCHEMBL6317887 | 0.71 | CA2 (0.31) | CA2NPC1RAB9AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143349-A1 | Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels | QUATRX PHARMACEUTICALS CO. | 2005-06-30 | — | — | US | claimed |
| US-20050143349-A1 | Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels | QUATRX PHARMACEUTICALS CO. | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143349-A1 | Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels | APOB, LDLR, LPL | CA2 2047/4885MAPT 4686/4885NPC1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.